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Deacetylase Inhibitors Increase Muscle Cell Size
by Promoting Myoblast Recruitment and Fusion
through Induction of Follistatin
myofibers (Charge and Rudnicki, 2004). Myoblasts de-
rived from patients with congenital myotonic dystrophy
have both an impaired proliferation and fusion capabili-
ties (Furling et al., 2001). An increase in the size of pre-
formed myotubes can occur in response to chronic
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Moreover, mouse embryos exposed to HDAC inhibitors
display anticipated and increased formation of somites,Summary
paired structures of mesodermal cells that give rise to
skeletal muscle precursors (Iezzi et al., 2002). Here, weFusion of undifferentiated myoblasts into multinucle-
ated myotubes is a prerequisite for developmental report on the cellular processes influenced by HDAC
inhibitors and the identification of the molecule(s) thatmyogenesis and postnatal muscle growth. We report
that deacetylase inhibitors favor the recruitment and mediate their effects on skeletal muscle growth and re-
generation.fusion of myoblasts into preformed myotubes. Muscle-
restricted expression of follistatin is induced by de-
acetylase inhibitors and mediates myoblast recruit- Results
ment and fusion into myotubes through a pathway
distinct from those utilized by either IGF-1 or IL-4. Deacetylase Inhibitors Stimulate Recruitment
Blockade of follistatin expression by RNAi-mediated of Myoblasts into Myotubes
knockdown, functional inactivation with either neu- To investigate whether HDAC inhibitors favor the recruit-
tralizing antibodies or the antagonist protein myosta- ment of myoblasts into myotubes or act as hypertrophic
tin, render myoblasts refractory to HDAC inhibitors. agents on preformed myotubes, we exposed C2C12
Muscles from animals treated with the HDAC inhibitor skeletal muscle cells at different stages of differentiation
trichostatin A display increased production of fol- to the HDAC inhibitor trichostatin A (TSA). Myoblasts
listatin and enhanced expression of markers of regen- exposed to TSA in high-serum medium (growth condi-
eration following muscle injury. These data identify tions) and then allowed to differentiate in low-serum
follistatin as a central mediator of the fusigenic effects medium (differentiation conditions) in the absence of
exerted by deacetylase inhibitors on skeletal muscles TSA form hypernucleated myotubes with increased cell
and establish a rationale for their use to manipulate size (Figure 1A). At the doses employed (50 nM), TSA
skeletal myogenesis and promote muscle regener- did not induce apoptosis or signs of cell toxicity (data
ation. not shown). IGF-1 promotes hypertrophy of preformed
myotubes (Rommel et al., 2001). Therefore, we exposed
Introduction 2-day-old myotubes to either IGF-1 or TSA. To eliminate
the possibility that either IGF-1 or TSA could act on
During embryo development, skeletal myofibers derive undifferentiated myoblasts present in the myotube cul-
from the fusion and differentiation of undifferentiated ture, arabinoside-C was added to the medium of 2-day-
myoblasts. After birth, in response to exercise and injury old myotubes for 24 hr before adding IGF-1 or TSA. As
and during degenerative diseases, quiescent satellite expected, IGF-1 induced myotube hypertrophy, while
cells become activated and fuse into new or pre-existing TSA failed to cause any appreciable increase in cell size
(Figure 1B). TSA does not stimulate cell proliferation
(Figure 1C), excluding the possibility that the formation*Correspondence: sartorev@mail.nih.gov
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Figure 1. TSA Increases Myoblasts Recruitment and Fusion
(A) C2C12 myoblasts were exposed to TSA (50 nM) in growth medium and then prompted to differentiate for 48 hr in the absence of
TSA. Immunofluorescence and immunoblot were performed with anti-MHC and anti-tubulin monoclonal antibodies. Nuclei were revealed by
DAPI staining.
(B) 2-day-old C2C12 myotubes were treated with ara-C (10 M) for 24 hr and subsequently exposed to either recombinant IGF-1 (10 ng/ml)
or TSA (50 nM) for 24 hr and immunostained with anti-MHC and DAPI.
(C) C2C12 myoblasts (1.2  105 cells/plate) were either mock-treated or exposed to TSA (50 nM) for 18 hr after which the nuclei, revealed by
DAPI staining, were counted (growth medium, GM). For the remaining time points, cells were cultured for an additional 24 hr in GM and then
switched to differentiation medium (DM). Nuclei were counted after 24 and 48 hr, respectively. Cells for every experimental point (both control
and TSA-treated) were plated and the nuclei counted in duplicate samples. The reported values were obtained after counting at least 5
microscopic fields.
(D) C2C12 myoblasts were cultured as described in (A) and immunostained with anti-MHC. The nuclei were revealed by DAPI staining. The
number of nuclei present in MHC cells/number of total nuclei per field was determined and expressed as percentage. Nuclei present in 10
microscopic fields were counted.
(E) Human primary skeletal myoblasts were exposed to TSA for 24 hr in GM and then cocultured in DM, in the absence of TSA, with preformed
mouse primary myotubes. For TSA-treated cells, two different microscopic fields are shown (TSA). Control represents human primary skeletal
myoblasts cells not exposed to TSA and cocultured with preformed mouse primary myotubes. Immunofluorescence was performed with anti-
MHC, and nuclei were revealed by DAPI staining. Nuclei of mouse origin (m) show punctuated reactivity to DAPI, while human nuclei (h)
display homogenous DAPI staining. Arrows indicate human nuclei in murine myotubes.
(F) Mouse C2C12 myoblasts were exposed to TSA or VPA for 24 hr in growth medium and then cocultured in differentiation medium, in the
absence of either TSA or VPA, with preformed human skeletal myotubes. The data are representative of the percentage of the fusion rate of
mouse cells into human myotubes (1–2 mouse nuclei per human myotube), as evaluated by counting 6 microscopic fields in duplicate experi-
ments.
consequence of an increased number of undifferenti- to TSA. Human myoblasts are easily identified as they
do not express MHC and have a homogenous nuclearated myoblasts available for the fusion process. These
findings suggest that TSA promotes neither hyperplasia reactivity to DAPI. On the contrary, murine myotubes
express MHC and display a characteristically punctu-nor hypertrophy, but rather that it acts as an inducer of
myoblast fusion, as indicated by the increased fusion ated nuclear pattern upon DAPI staining (Tapscott et
al., 1993). As shown in Figure 1E, exposure of humanindex (Figure 1D). To further test the hypothesis that
TSA favors myoblast fusion, we performed coculturing primary myoblasts to TSA prior to coculturing results
in the presence of mouse myotubes containing humanexperiments. Mouse primary myotubes were cocultured
with human primary adult myoblasts previously exposed nuclei, whereas nuclei from untreated human myoblasts
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cannot be detected in mouse myotubes. In reciprocal is one of the most highly upregulated transcripts (28-
fold, Supplemental Table S1) and because of its reportedexperiments, differentiated human primary myotubes
role in muscle development (Lee and McPherron, 2001;were cocultured with undifferentiated mouse myoblasts
Matzuk et al., 1995). In the absence of TSA, follistatinexposed to either TSA or valproic acid (VPA), another
transcription was initiated after 4–12 hr of culture inHDAC inhibitor. Prior exposure of mouse myoblasts to
differentiation medium and steadily increased over theeither deacetylase inhibitors augmented the percentage
next 48 hr (Figure 2G, Control). While being consistentlyof human myotubes containing mouse nuclei (Figure
elevated in every sample of TSA-treated cells, the fol-1F). Notably, the fusigenic effect of deacetylase inhibi-
listatin transcripts displayed two peaks at 4 and 48 hrtors was restricted to myogenic cells, since exposure
(Figure 2G, TSA). The transcriptional profile of follistatinto TSA or VPA did not stimulate the fusion of fibroblasts
was independently analyzed by RT-PCR and found toor other nonmuscle cells into preformed myotubes (data
be concordant with that observed using microarray anal-not shown). Altogether, the results of these experiments
ysis (Figure 2G, lower panel). VPA and sodium butyrate,suggest that inhibitors of class I-II HDACs stimulate spe-
another HDAC inhibitor, also increased follistatin ex-cific recruitment of undifferentiated myoblasts into dif-
pression (Figure 2H). To investigate whether HDAC in-ferentiated myotubes.
hibitors induce follistatin expression in a cell type-spe-
cific manner, mouse primary keratinocytes, C2C12 cells
The Effects of TSA Are Unlikely to Be Mediated (Figures 3A and 3B), and mouse primary myoblasts (Fig-
by Either the IGF-1 or IL-4 Pathways ures 3C and 3D) were exposed to either TSA, sodium
The increased myoblast accretion and fusion induced butyrate, or VPA for 18 hr and induced to differentiate.
by HDAC inhibitors appear to be achieved through a HDAC inhibitors increased follistatin levels in C2C12 and
pathway distinct from that of IGF-1-mediated muscle primary myoblasts but not in keratinocytes, which also
hypertrophy (Figure 1B). Expression of neither GATA2 failed to upregulate follistatin during differentiation (Fig-
nor IGFBP5, two markers of IGF-1 activation (Musaro ures 3A–3D). Similarly, HDAC inhibitors could not aug-
and Rosenthal, 1999), was increased by TSA (Figures ment follistatin expression in C3H10T1/2 and NIH3T3
2A and 2B). Moreover, blocking the activation of the mouse fibroblasts, as well as in the adipogenic 3T3-L1
PI(3) kinase, a downstream effector of IGF-1, with the and the osteogenic MC3T3-E1 cell lines (Figures 3E and
specific inhibitor LY294002 only slightly reduced (ap- 3F). Follistatin expression has been previously reported
proximately 15%) the ability of TSA to promote myo- to be stimulated by IL-1 in pituitary cells (Bilezikjian
blasts fusion (Figure 2C). Next, we investigated whether et al., 2003). To investigate the cell type specificity of
TSA may increase expression of IL-4, a cytokine recently follistatin induction in response to different stimuli, we
shown to be involved in myoblast fusion (Horsley et al., compared the responses of C2C12 myoblasts and TtT/
2003). Both microarray (see Supplemental Data at http:// GF pituitary cells to IL-1 and TSA. IL-1 activated fol-
www.developmentalcell.com/cgi/content/full/6/5/673/ listatin expression in TtT/GF cells but not C2C12 myo-
DC1) and RT-PCR (Figure 2D) experiments failed to de- blasts, while TSA specifically upregulated follistatin lev-
tect an increased expression of IL-4 following TSA treat- els only in C2C12 cells (Figures 3G and 3H). Collectively,
ment. These results indicate that deacetylase inhibitors these results suggest that HDAC inhibitors may modu-
promote the formation of myotubes with an increased late follistatin expression in a cell type-specific fashion.
size through a pathway independent from those em-
ployed by either IGF-1 or IL-4. Follistatin Has Effects Similar to Those Exerted
by TSA on Skeletal Muscle Cells
We evaluated whether follistatin may have effects similar
Temporal Expression Profiling of Skeletal Muscle to those exerted by TSA on muscle cells by enforcing
Cells Exposed to TSA Reveals a Muscle- its expression in skeletal myoblasts. Cells expressing
Specific Induction of Follistatin exogenous follistatin (Figure 4A) displayed increased
We sought to identify the molecular effectors of HDAC number of nuclei and cell size (Figure 4B) and increased
inhibitors by profiling gene expression of myoblasts ex- fusion index (Figure 4E). To continue investigating
posed to TSA. RNAs were isolated at 0, 4, 12, 24, and whether follistatin has properties similar to those of TSA,
48 hr of culture in differentiation medium (Figure 2E). A skeletal muscle cells were exposed to recombinant fol-
comprehensive analysis of the genes whose expres- listatin at different stages of differentiation. As for TSA
sion is modulated by TSA at different time points is treatment, follistatin did not increase the size of pre-
reported in Supplemental Data and is available at http:// formed myotubes (Figures 4C, rFS on myotubes, and
microarray.cnmcresearch.org. Using stringent analysis 4E). In contrast, myoblasts cultured in the presence of
(at least 15 “present” calls for 20 experimental points, follistatin and prompted to differentiate formed hyper-
1% expected false positive rate, see Supplemental nucleated myotubes with increased size, due to en-
Data), expression of 435 out of 4300 interrogated genes hanced fusion (Figures 4D, rFS on myoblasts, and 4E).
(10% of identified genes) was found to be modulated The effects exerted by TSA on myoblasts are unlikely
by TSA. A partial list of the transcripts increased by TSA to be mediated by IL-4 (Figure 2). To evaluate whether
is reported in Supplemental Table S1. Using RT-PCR, follistatin could indirectly activate IL-4 expression, we
we confirmed that several transcripts were indeed ele- performed an RT-PCR assay on RNA isolated from
vated in TSA-treated cells. These include those for MHC, C2C12 expressing myc-follistatin and found no signs of
pRb, muscle glycogen synthase (Figure 2F), and fol- IL-4 induction (Figure 4F). Therefore, it appears that the
listatin (Figure 2G), a protein that interacts with members effects exerted by follistatin on muscle cells are similar
to those exerted by HDAC inhibitors.of the TGF- family. We focused on follistatin since it
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Figure 2. Expression Profiling Analysis of Transcripts Modulated by TSA
(A and B) Microarray analysis of transcripts corresponding to GATA-2 and IGFBP5 in control and TSA-treated cells at different time points
(see below).
(C) Myoblasts cultured in wells coated with 0.1% gelatin were exposed to either LY294002 (10 M), TSA (50 nM), or both LY294002 and TSA
for 18 hr in GM and allowed to differentiate in DM for 48 hr before immunostaining with anti-MHC and DAPI.
(D) IL-4 mRNA expression was analyzed by RT-PCR in T lymphocytes activated with CD3/28 and IL-2, unstimulated T lymphocytes, untreated
and TSA-treated C2C12 cells.
(E) Experimental design and time frame. Myoblasts were exposed to TSA (50 nM) for 18 hr in GM. The medium was then replaced with DM
without TSA and cells harvested at 0, 4, 12, 24, and 48 hr and processed for RNA extraction. Control cells were without TSA.
(F) RT-PCR of transcripts for MHC, pRb, glycogen synthase, and GAPDH in untreated and TSA-treated cells.
(G) Microarray and RT-PCR time course of follistatin and GAPDH transcripts following TSA treatment.
(H) Myoblasts were exposed to either valproic acid (10 mM) or sodium butyrate (10 mM) and allowed to differentiate for 48 hr. Follistatin and
GAPDH expression were evaluated by RT-PCR.
MyoD, CREB, and NFAT Mediate effect (Figure 5C, lane 4). The negative regulator of MyoD
Id1 blocked induction mediated by either MyoD (Figurethe Transcriptional Activation
of the Follistatin Promoter Induced by TSA 5C, lane 5) or MyoD and CREBY134F (Figure 5C, lane 8).
Similarly, A-CREB—a dominant-negative form of CREBTo investigate the effects of TSA on follistatin transcrip-
tion, the follistatin promoter linked to luciferase (FS-luc) (Ahn et al., 1998)—reduced transactivation elicited by
either CREBY134F (Figure 5C, lane 6) or CREBY134Fwas transfected in skeletal myoblasts. TSA activated
transcription of FS-luc (Figure 5A). Within the follistatin and MyoD (Figure 5C, lane 7), suggesting that both
MyoD and CREB are required to activate follistatin tran-proximal promoter, there are an E box, a CRE element,
and a consensus site for NFAT (Figure 5B). To ascertain scription. NFATc2, either alone (Figure 5D, lane 3) or in
combination with CREBY134F (Figure 5D, lane 7), didwhether MyoD, CREB, and NFAT could activate FS-
luc, we transfected murine fibroblasts with the FS-luc not significantly activate FS-luc. Nonetheless, NFATc2
increased MyoD-dependent follistatin activation (Figurereporter and expression vectors for MyoD, a form of
constitutively active CREB (CREB Y134F) (Du et al., 5D, lane 4), and cotransfection of a plasmid expressing
VIVIT, a peptide that blocks NFAT-dependent transacti-2000) and NFATc2. Either MyoD or CREBY134F acti-
vated FS-luc transcription (Figure 5C, lanes 2 and 3, vation (Aramburu et al., 1999), abrogated the transcrip-
tional synergism exerted by NFATc2 and MyoD (Figurerespectively) and their cotransfection had an additive
HDAC Inhibitors Promote Myoblast Recruitment
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Figure 3. HDAC Inhibitors Activate Follistatin Expression in a Cell Type-Specific Fashion
(A) Primary mouse keratinocytes and C2C12 cells were cultured in either the absence or presence of TSA, sodium butyrate, or VPA for 18 hr
and induced to differentiate (D) for 48 hr in the absence of HDAC inhibitors. Untreated, undifferentiated keratinocytes (U) were also included
in the experiment. Follistatin and GAPDH expression was evaluated by RT-PCR.
(B) Quantitation of the data presented in (A). The intensity of the signals corresponding to the follistatin and GAPDH bands were determined
using the NIH Image software package. The follistatin signals were corrected for the GAPDH signals.
(C) Mouse primary satellite cells were cultured without or with HDAC inhibitors for 18 hr and induced to differentiate (D) for 48 hr in the
absence of HDAC inhibitors. U, undifferentiated satellite cells. RT-PCR analysis of follistatin and GAPDH.
(D) Quantitation of the data reported in (C).
(E) C3H10T1/2, NIH 3T3 mouse fibroblasts, 3T3-L1 adipogenic, and MC3T3-E1 osteogenic cells were cultured in either the absence or presence
of TSA for 18 hr and for an additional 48 hr in the absence of TSA. RT-PCR analysis of follistatin and GAPDH.
(F) Quantitation of the data reported in (E).
(G) TtT/GF pituitary cells and C2C12 were exposed to either recombinant IL-1 (2 nM) or TSA (50 nM) for 18 hr, cultured for an additional 24
hr, and processed for RT-PCR.
(H) Quantitation of the data reported in (G).
5D, lane 5). Cotransfection of MyoD, CREBY134F, and presence of MyoD, CREB, and NFATc2 at the follistatin
promoter and evaluated whether TSA treatment modu-NFATc2 resulted in additive transactivation (Figure 5D,
lane 8). Individual and combinatorial mutations of the lated promoter occupancy by ChIP assay. Chromatin
obtained from C2C12 cells that were either untreatedbinding sites for MyoD, CREB, and NFAT impaired FS-
luc transcription (data not shown). To establish the role or exposed to TSA and prompted to differentiate for 4 hr
was immunoprecipitated with control immunoglobulin,of MyoD, CREB, and NFATc2 in TSA-mediated activa-
tion of the FS-luc reporter, skeletal myoblasts were anti-MyoD, anti-CREB, and anti-NFATc2 antibodies.
Since TSA induces MyoD hyperacetylation (Iezzi et al.,transfected with FS-luc and with one expression vector
(either for Id1, A-CREB, or VIVIT) and exposed to TSA. 2002) and prolongs CREB phosphorylation upon for-
skolin treatment (Michael et al., 2000), we also monitoredTSA-mediated transcriptional activation of the FS-luc
reporter was inhibited by either Id1 (Figure 5E, lane 3), binding of the acetylated MyoD and phosphorylated
CREB, respectively. While total and phosphorylatedA-CREB (Figure 5E, lane 4), or VIVIT (Figure 5E, lane 5).
Collectively, these results suggest that MyoD, CREB, CREB (Figure 5F) and NFATc2 (Figure 5G) are recruited
on the chromatin regardless of TSA treatment, total andand NFAT may be involved in mediating the effect of
TSA on follistatin transcription. We investigated the acetylated MyoD were found on the follistatin promoter
Developmental Cell
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Figure 4. Follistatin Increases Myoblasts Fusion
(A) Myc-follistatin protein of the expected molecular weight is expressed in myc-follistatin-transduced cells.
(B) Skeletal myoblasts transduced with either a control or myc-follistatin-expressing retrovirus were cultured in DM for 48 hr before immuno-
staining with anti-MHC.
(C and D) Skeletal myotubes (C) and myoblasts (D) were cultured in the presence of recombinant follistatin (rFS, 0.2 g/ml) and immunostained
for MHC.
(E) The number of nuclei present in MHC cells over the total number of nuclei present in at least 10 microscopic filed (expressed as percentage)
was determined in control, myc-follistatin-expressing cells, and in myotubes (MT) and myoblasts (MB) cultured in the presence of recombinant
follistatin with DAPI staining.
(F) IL-4 mRNA expression was analyzed by RT-PCR in T lymphocytes activated with CD3/28 and IL-2, C2C12 and C2C12 cells expressing
myc-follistatin.
only after exposure to TSA (Figure 5H). Histones H3 and peptide that blocks NFAT activation (Aramburu et al.,
H4 at the follistatin promoter were acetylated after 4 hr 1999), had decreased follistatin transcripts (Figure 6C)
of culturing cells in differentiation medium, and expo- and failed to appropriately respond to TSA (Figures 6D–
sure to TSA further increased their acetylation (Figure 6F). Follistatin binds the carboxyl terminus of myostatin
5I). The results of the experiments indicate that the fol- and counteracts myostatin activity (Lee and McPherron,
listatin promoter is cooperatively activated by MyoD, 2001). We attempted to block the activity of endogenous
CREB, and NFATc2 and that TSA induces binding of follistatin by culturing skeletal myoblasts exposed to
MyoD and local hyperacetylation at the follistatin pro- TSA with recombinant myostatin. Myostatin counter-
moter. acted the effects of TSA (Figure 7A, myostatinTSA).
To verify the involvement of follistatin in this phenome-
Follistatin Is Necessary to Mediate the Effects non, we performed a reciprocal experiment and added
of TSA and Counteracts Myostatin Activity recombinant follistatin to skeletal muscle cells cultured
To test the hypothesis that follistatin is required to medi-
in the presence of both recombinant myostatin and TSA.
ate the effects exerted by TSA, we employed five differ-
Under these conditions, we observed that the effectsent and complementary experimental approaches. Skel-
of TSA treatment were restored (Figure 7A, myostatinetal myoblasts were first infected with an adenovirus
rFSTSA). Using a different approach, we cultured skel-expressing the dominant-negative A-CREB (Herzig et
etal myoblasts with TSA and employed antibodies di-al., 2001) and then exposed to TSA. Consistent with a
rected against follistatin to neutralize its bioactivity. Thepositive role of CREB in mediating the transcriptional
presence of neutralizing follistatin antibodies, but noteffects of TSA (Figure 5), cells infected with A-CREB
of control immunoglobulins, greatly reduced TSA-medi-displayed a reduced expression of endogenous fol-
ated myoblasts fusion (Figures 7B and 7C). Finally, welistatin (Figure 6A) and did not form hypernucleated myo-
reduced follistatin in skeletal myoblasts by infectingtubes (Figure 6B) after TSA treatment. Similarly, myo-
blasts transduced with a retrovirus expressing VIVIT, a them with a retrovirus expressing a short hairpin (sh)
HDAC Inhibitors Promote Myoblast Recruitment
679
Figure 5. The Follistatin Promoter Is Activated by TSA through MyoD, CREB, and NFAT
(A) The follistatin promoter linked to luciferase (FS-luc) was transfected in C2C12 myoblasts and the cells exposed to TSA or left untreated.
The parental luciferase vector (-luc) was employed as control. The cells were differentiated for 48 hr in DM without TSA and harvested, and
the luciferase activity was determined.
(B) Schematic representation of the follistatin promoter indicating the presence of binding sites for NFAT, MyoD, and CREB.
(C) The FS-luc reporter and expression vectors for MyoD, CREBY134F, Id1, and A-CREB were transfected into C3H10T1/2 fibroblasts in
different combinations. Cells were induced to differentiate for 48 hr and the luciferase activity determined.
(D) The FS-luc reporter and expression vectors for MyoD, NFAT2C, VIVIT, and CREBY134F were transfected into C3H10T1/2 fribroblasts in
different combinations.
(E) The FS-luc reporter and expression vectors for either Id1, A-CREB, or VIVIT were transfected into C2C12 myoblasts. The cells were then
either exposed to TSA or left untreated and induced to differentiate for 48 hr in the absence of TSA. Every experiment described in this figure
was done in triplicate and repeated 3–5 times.
(F) ChIP using control IgG, anti-phospho CREB (phos), or anti-total CREB (total) antibodies. I, input DNA. The follistatin and GAPDH promoter
regions were PCR-amplified.
(G) ChIP using either control IgG or anti-NFAT1/2C (N) antibodies. I, input DNA.
(H) Chromatin derived from untreated or TSA-treated C2C12 cells was immunoprecipitated using control IgG, anti-acetylated MyoD (acetyl),
or anti-total MyoD (total) antibodies. I, input DNA.
(I) ChIP using control IgG, anti-diacetylated histone H3 (H3), or anti-tetracetylated histone H4 (H4) antibodies. I, input DNA.
RNA-targeting follistatin. Cells transduced with sh RNA satellite cell activation is associated with increased fol-
listatin gene expression, we analyzed temporal expres-follistatin and exposed to TSA had decreased levels of
follistatin upon TSA stimulation (Figure 7D) and were less sion profiling data generated in a mouse model of mus-
cle injury and regeneration (Zhao et al., 2002). Twelveresponsive to TSA compared to control cells (Figures
7E–7G). Taken together, the results reported in this para- hours after injury, the levels of follistatin were increased
7-fold and remained elevated (approximately 2-fold) forgraph strongly suggest that myoblasts with reduced
levels of follistatin become refractory to TSA treatment. 5 days (Supplemental Figure S1). A later peak of fol-
listatin expression (2- to 3-fold increase) was noted
starting from day 10 and persisted until day 30. To deter-Follistatin Expression Is Induced upon Muscle
Injury and Coincides with Expression of mine whether follistatin activation coincides with the
appearance of activated satellite cells, we analyzed theMarkers of Satellite Cell Activation
HDAC inhibitors induce follistatin gene expression in expression of several markers of satellite cells activa-
tion. Msx1 is transcribed in quiescent satellite cells andmouse primary myoblasts (Figure 3). To evaluate whether
Developmental Cell
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Figure 6. A-CREB, a Dominant-Negative Form of CREB, and VIVIT, a Peptide Blocking the NFAT Activity, Reduce Follistatin Transcription
and Render Myoblasts Refractory to TSA
(A) C2C12 myoblasts were infected with adenoviruses coding for either GFP and A-CREB, GFP and CREB Y134F, or GFP alone. After 24 hr,
cells were exposed to TSA for an additional 24 hr in GM and then incubated in DM for 12 hr. Extracted RNA was employed in RT-PCR analysis
with primers for follistatin or GAPDH.
(B) C2C12 myoblasts were infected with adenoviruses coding for either GFP alone or GFP and A-CREB. After 24 hr, cells were exposed to
TSA for an additional 24 hr in GM and then incubated in DM for 36 hr. Infected cells were detected by GFP fluorescence.
(C and D) Retroviruses coding for either GFP alone or GFP and VIVIT were employed to transduce C2C12 myoblasts. After the infection, the
cells were either exposed to TSA or left untreated for 18 hr and induced to differentiate in the absence of TSA for an additional 48 hr. Total
RNA was isolated and RT-PCR performed with primers for follistatin and GAPDH. In parallel experiments, cells were fixed and visualized by
GFP. Nuclei were stained with DAPI.
(E) The number of nuclei present in MHC cells over the total number of nuclei present in at least 10 microscopic filed (expressed as percentage)
was determined in cells transduced with either GFP or GFP-VIVIT and exposed to TSA.
(F) Anti-MHC immunoblot of total extracts derived from cells transduced with either GFP or VIVIT-GFP retrovirus and exposed or not to TSA.
its expression is extinguished upon cell activation (Cor- was systemically delivered to adult female mice with
nelison et al., 2000). On the other hand, only activated subcutaneous micro-osmotic pumps. After 2 days of
satellite cells express MyoD (Cornelison and Wold, TSA treatment, the tibialis anterior muscles were in-
1997), Numb (Conboy and Rando, 2002), and, at later jected with cardiotoxin. TSA delivery was continued for
stages, myogenin (Cornelison and Wold, 1997). Twelve 3 additional days, after which the animals were sacri-
hours after muscle injury, we noted that expression of ficed. At this time, muscle regeneration has been initi-
Msx1 was reduced while MyoD and Numb expression ated (Charge and Rudnicki, 2004). The expression levels
increased. Myogenin expression increased 4 days fol- of follistatin in noninjured muscles was almost undetect-
lowing injury. M-cadherin, a late marker of satellite cells able and increased upon injury (data not shown and
activation (Cornelison and Wold, 1997), was also highly Supplemental Figure S1). TSA administration further in-
expressed at 72 hr after injury (Supplemental Figure S1). duced follistatin expression in injured muscles (40% in-
Altogether, this analysis indicates that following skeletal crease, Figures 8A and 8B). At variance, the sole TSA
muscle injury, follistatin gene expression is induced with treatment did not affect follistatin gene expression in
a kinetic similar to that of markers of satellite cell acti- noninjured muscles (data not shown). To investigate
vation. whether the increased follistatin expression caused by
the combination of TSA treatment and muscle injury was
accompanied by augmented muscle regeneration, weTSA Promotes Expression of Follistatin
evaluated expression of the embryonic (emb) and peri-and of Markers of Muscle Regeneration
natal/neonatal (peri) isoforms of myosin heavy chainWe next wished to evaluate whether HDAC inhibitors
may affect muscle regeneration in vivo. To this end, TSA (MHC), two markers of muscle regeneration (Whalen et
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Figure 7. Blockade or Knockdown of Follistatin Abrogates the Effects of TSA on Myoblast Fusion
(A) C2C12 myoblasts were cultured in the presence of either TSA, recombinant follistatin, or myostatin. TSA-mediated increased myoblast
fusion (TSA) was blocked by recombinant myostatin (100 ng/ml) (myostatinTSA). Addition of recombinant follistatin (0.2 g/ml) restored the
ability of TSA to augment myoblast fusion in the presence of myostatin (myostatinrFSTSA).
(B) Myoblasts were exposed to TSA in the presence of either control IgG (4 g/ml) or anti-follistatin antibodies (4 g/ml).
(C) The number of nuclei present in MHC cells/number of total nuclei per field was determined and expressed as percentage.
(D) C2C12 myoblasts transduced with either pSUPER.retro (control) or pSUPER.retro bearing an oligonucleotide insert to target follistatin
transcripts (FS-RNAi) were exposed to TSA or left untreated before inducing differentiation for 48 hr. Total RNA was isolated and RT-PCR
performed with primers for follistatin and GAPDH.
(E) Control and FS-RNAi cells were either exposed to TSA or left untreated and induced to differentiate for 48 hr before immunostaining with
anti-MHC.
(F) Anti-MHC and anti-tubulin immunoblot of extracts derived from control and FS RNAi cells exposed to TSA or left unexposed.
(G) The number of nuclei present in MHC cells over the total number of nuclei (expressed as percentage) was determined in cells transduced
with either control or FS-RNAi retrovirus and exposed to TSA.
al., 1990; Hall-Craggs and Seyan, 1975). Muscle injury Discussion
caused expression of both emb and peri MHC, two iso-
We have identified follistatin as one of the most highlyforms that are not expressed in the adult animals (Lyons
induced transcripts in muscle cells treated with TSAet al., 1990) and whose presence reflects de novo fiber
and provided evidence to indicate that follistatin is anformation (Figures 8A and 8B; Charge and Rudnicki,
essential mediator of HDAC inhibitor-induced increase2004). Importantly, the combination of muscle injury and
of muscle size and satellite cell recruitment. FollistatinTSA treatment increased the expression levels of both
interacts with and regulates the biological activities ofemb and peri myosins to levels beyond those observed
several TGF- family members including BMP-4,in the presence of injury alone (Figures 8A and 8B).
BMP-7, and activins (Iemura et al., 1998; Amthor et al.,Altogether, these results indicate that systemic delivery
2002). Follistatin can also block the activity of myostatinof TSA, when associated to muscle injury, stimulate ex-
(Lee and McPherron, 2001) and of GDF-11, a moleculepression of follistatin and of at least two markers of
muscle regeneration in the adult animal. structurally and functionally related to myostatin
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myostatin for 3 months improve the dystrophic pheno-
type in the mdx mouse model of Duchenne muscular
dystrophy (Bogdanovich et al., 2002). An alternative
method to block myostatin may be through induction
of follistatin achieved via administration of HDAC inhibi-
tors. As for the potential teratogenic and toxic effects
of the deacetylase inhibitors, we note that doses of TSA
and VPA sufficient to enhance embryonal myogenesis
are not teratogenic (Iezzi et al., 2002) and that clinical
trials conducted with HDAC inhibitors indicate that they
are well tolerated at doses that cause accumulation of
acetylated histones in tissue biopsies (Marks et al.,
2001). Furthermore, the HDAC inhibitors seem to influ-
ence gene expression in a tissue-specific manner, pref-Figure 8. Systemic TSA Delivery in Injured Animals Increases Ex-
erentially activating follistatin expression in skeletalpression of Follistatin and of Markers of Muscle Regeneration
muscle cells and, in the animal, only in injured muscles(A) Three days after injury, RNA was extracted and RT-PCR analysis
(Figure 8). In support of the cell-specific effects of HDACconducted on crushed tibialis anterior muscles for follistatin, MHC
embryonic (emb), MHC perinatal/neonatal (peri), and GAPDH tran- inhibitors is the observation that sodium butyrate, rather
scripts of untreated (control) or TSA-treated (TSA) animals. than increasing it, reduces follistatin expression in cells
(B) Graphic showing the average of ratios of follistatin, MHCemb, derived from a colon adenocarcinoma (Germann et al.,
and MHC peri obtained from transcripts derived from either muscle- 2003). Myoblast transfer therapy (MTT) has been pro-injured control (C) or muscle-injured and TSA-treated (TSA) animals
posed for the treatment of DMD. Nonetheless, donorcorrected for their respective GAPDH. Mice (n  3) for each experi-
myoblasts are impaired in cell migration and fuse poorlymental point were treated for 7 days with either vehicle or TSA.
with recipient myotubes. Ex vivo exposure of donor
myoblasts to HDAC inhibitors may be useful to improve
the success of MTT through increased myoblasts fusion.(McPherron et al., 1997). Myostatin circulates as part of
Finally, intra-arterial delivery of mesoangioblasts, aa latent complex containing myostatin propeptide and/
class of vessel-associated stem cells, corrects the dys-or follistatin-related gene (FLRG) and GASP-1, two mole-
trophic phenotype of sarcoglycan null mice, a modelcules highly related to follistatin (Hill et al., 2002, 2003).
organism for limb-girdle muscular dystrophy (Sam-Both FLRG and GASP-1 inhibit the biological activity of
paolesi et al., 2003). Ex vivo treatment of mesangioblastsmyostatin. Our experiments indicate that recombinant
with HDAC inhibitors may increase their ability to bemyostatin blunts the effects of TSA treatment and that
recruited into regenerating dystrophic muscles and tofollistatin resumes the ability of TSA to induce myoblast
be used to optimize protocols of cell therapy.recruitment in the presence of myostatin. These experi-
ments suggest the possibility that follistatin may favor
Experimental Proceduresmyoblast recruitment by inhibiting the activity of myos-
tatin. Previous work has clearly indicated a role for fol- Cell Culture, Retroviruses, and Adenoviruses
listatin during developmental myogenesis as indicated C2C12, C3H10T1/2, and NIH3T3 cells were from ATCC and cultured
as described (Iezzi et al., 2002). TtT/GF pituitary cells, pre-adipo-by the muscle phenotypes of animals either deficient
genic 3T3-L1, and pre-osteoblastic MC3T3-E1 were cultured as de-for (Matzuk et al., 1995) or overexpressing (Lee and
scribed (Bilezikjian et al., 2003; Green and Meuth, 1974; Wang etMcPherron, 2001) follistatin. Our findings are consistent
al., 1999). Primary mouse keratinocytes were isolated and culturedwith follistatin also being relevant for adult myogenesis.
as described (Yuspa et al., 1989). The human follistatin cDNA fused
Follistatin expression is induced in muscle biopsies ob- to myc epitope (Sidis et al., 2001) was cloned into the pBabe-Puro
tained in mouse models of degeneration/regeneration retroviral vector. The GFP-VIVIT retroviral vector (Friday et al., 2000)
and the GFP-A-CREB adenoviral vector have been described (Herzig(Figure 3 and Supplemental Data; Armand et al., 2003).
et al., 2001).Primary adult satellite cells exposed to HDAC inhibitors
activate follistatin expression and have an increased
Plasmids and Transfectionsfusion index. Furthermore, increased myoblast recruit-
500 bp of the rat follistatin proximal promoter linked to the luciferase
ment is observed in coculturing experiments performed was derived from the 2.8 Kb rat follistatin promoter-luciferase con-
with primary adult satellite cells treated with HDAC in- struct (Bilezikjian et al., 2001). Transfections were performed with
the FuGENE6 reagent (Roche, Indianapolis, IN).hibitors. Most importantly, our experiments reveal that
delivery of TSA to animals with muscle injury stimulates
Immunoblotting and Immunofluorescencefollistatin production and expression of two embryonic
Cells were lysed in 50 mM Tris-HCl (pH 8.0), 125 mM NaCl, 1 mMforms of MHC, a reflection of de novo fiber formation.
DTT, 5 mM MgCl2, 1 mM EDTA, 10% glycerol, and 0.1% NP-40TSA fails to activate the expression of follistatin in nonin- supplemented with 1 mM PMSF and protease inhibitor mix. For
jured muscle, indicating that deacetylase inhibitors exert immunofluorescence, cells were fixed in 4% paraformaldehyde, per-
meabilized with 0.3% Triton X-100, and blocked with PBS containingtheir pharmacological biological activity only on acti-
3% bovine serum albumin.vated satellite cells. These findings establish a rationale
for the employment of HDAC inhibitors in clinical situa-
TSA Treatment and Expression Profilingtions where muscle regeneration is desirable. Pertinent
C2C12 myoblasts were exposed to TSA for 16–18 hr in DMEM media
to adult myogenesis in pathological conditions is the supplemented with 20% fetal calf serum and then switched to
observation that either loss of myostatin (Wagner et al., DMEM without TSA and containing 2% horse serum, 1 insulin,
transferrin, and selenium. Total RNA was extracted using the TRIzol2002) or chronic injection of blocking antibodies against
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